Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Офтальмология / Английские материалы / Carbonic Anhydrase Its Inhibitors and Activators_Supuran, Scozzafava, Conway_2004

.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
9.01 Mб
Скачать

154

Carbonic Anhydrase

TABLE 5.3

Activity Data Used by Carotti et al.a to Derive QSAR for Benzenesulfonamides

 

 

X-C6H4-SO2NH2

 

 

X

log 1/KI

 

X

log 1/KI

1

H

5.50

17

4-Br

6.70

2

3-Me

5.60

18

4-I

7.08

3

3-i-Pr

5.40

19

4-NH2

4.82

4

3-Cl

6.34

20

4-OMe

5.92

5

3-Br

6.42

21

4-COMe

6.85

6

3-I

6.21

22

4-SO2NH2

7.04

7

3-NH2

5.28

23

4-O-n-Bu

7.03

8

3-OMe

5.49

24

4-i-Pr

6.63

9

3-COMe

5.44

25

4-NO2

6.43

10

3-CONH2

4.90

26

4-CN

6.53

11

3-SO2NH2

5.79

27

4-Ph

7.19

12

3-O-n-Bu

5.86

28

4-OH

5.13

13

3-NO2

6.28

29

4-OHx

7.20

14

3-CN

6.14

30

4-NHCOMe

5.43

15

4-Me

5.85

31

4-NHSO2CH3

5.32

16

4-Cl

6.76

32

3-NO2-2,4-(OH)2

7.56

a Carotti, A. et al. (1989) QSAR 8, 1–10.

TABLE 5.4

Activities of the Group of Benzenesulfonamides Studied by DeBenedetti et al.a

 

R

log II50 obs

 

R

log II50 obs

1

4-NH2

0.00

14

4-CN

1.32

2

4-NHMe

0.18

15

4-Cl

1.08

3

2-Me

0.16

16

3-Cl

1.00

4

3,4-Me2

0.48

17

2-Cl

0.88

5

4-OMe

0.71

18

3,4-Cl2

1.76

6

4-NHCOMe

1.48

19

4-NO2

1.41

7

2-NH2

0.66

20

3-NO2

1.25

8

4-Me

0.78

21

3-SO2NH2

1.87

9

3-NH2

0.40

22

4-SO2NH2

2.00

10

3-Me

0.66

23

3-CF3-4-NO2

2.21

11

H

0.58

24

3-NO2-4-Cl

2.13

12

4-COMe

1.32

25

2-NO2

0.43

13

3-Me-4-Cl

1.74

 

 

 

a DeBenedetti et al. (1985) QSAR 4, 23–28.

Copyright © 2004 CRC Press, LLC

QSAR Studies of Sulfonamide Carbonic Anhydrase Inhibitors

155

TABLE 5.5

Sulfanilamide Schiff’s Bases Studied by Supuran and Clarea

 

R2

 

SO2NH2

 

 

 

 

 

 

N

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

R1

 

 

 

 

 

 

 

 

 

 

 

 

 

CICA

 

 

 

 

 

 

 

 

 

 

I(106

CICA II

No.

R1

 

R2

M)

(108 M)

1

Phenyl

H

18

27

2

2-Hydroxyphenyl

H

35

41

3

2-Nitrophenyl

H

9

21

4

4-Chlorophenyl

H

25

28

5

4-Hydroxyphenyl

H

14

19

6

4-Methoxyphenyl

H

13

19

7

4-Dimethylaminophenyl

H

10

8

8

4-Nitrophenyl

H

13

5

9

4-Cyanophenyl

H

4

11

10

3-Methoxy-4-hydroxyphenyl

H

5

8

11

3,4-Dimethoxyphenyl

H

7

3

12

3-Methoxy-4-acetoxyphenyl

H

3

10

13

2,3-Dihydroxy-5-formylphenyl

H

4

2

14

2-Hydroxy-3-methoxy-5-formylphenyl

H

5

3

15

3,4,5-Trimethoxyphenyl

H

5

3

16

3-Methoxy-4-hydroxy-5-bromophenyl

H

12

4

17

2-Furyl

H

3

5

18

5-Methyl-2-furyl

H

3

4

19

Pyrol-2-yl

H

5

2

20

Imidazol-4(5)-yl

H

1

12

21

2-Pyridyl

H

2

9

22

3-Pyridyl

H

4

8

23

4-Pyridyl

H

4

5

24

Styryl

Me

14.4

0.39

25

4-Methoxystyryl

Me

9.4

0.12

26

4-Dimethylaminostyryl

Me

0.6

0.10

27

3,4,5-Trimethoxystyryl

Me

1.3

0.24

28

Styryl

Ph

20.9

0.56

29

4-Methoxystyryl

Ph

19.0

1.50

30

4-Dimethylaminostyryl

Ph

16.0

1.69

31

3,4,5-Trimethoxystyryl

Ph

10.7

2.35

32

3,4,5-Trimethoxystyryl

4-MeOC6H4

12.5

1.27

33

3-Nitrostyryl

4-MeOC6H4

6.3

0.65

34

3,4,5-Trimethoxystyryl

4-H2NC6H4

10.6

0.85

35

3,4,5-Trimethoxystyryl

4-PhC6H4

25.0

2.48

a Supuran, C.T., and Clare, B.W. (1998) European Journal of Medicinal Chemistry 33, 489–500.

Copyright © 2004 CRC Press, LLC

156

Carbonic Anhydrase

Values of pKa for the sulfonamide group calculated by the Pallas software were also included. They derived the following equation for CA II:

− log Kii = 0.0651(±0.0212)Dx + 9916(±3917)QH − 6614(±(2408)QH2

− 1.1921(±0.2413)Ip + 603.5(±57.8)(SpE SmE 2)

(5.7)

+ 113.6(±21.1)(Qm + Qp ) − 4007.0(±1592.5)

(n = 35, R2 = 0.854, s = 0.274, F = 27.5)

where Dx is the component of the dipole moment in the direction of the benzene carbon–sulfur bond, QH the charge on the sulfonamide protons, Ip an indicator variable related to lipophilicity, (SpE SmE/2) the difference in electrophilic superdelocalizability between the p- and the average of the two m-atoms of the sulfanilamide benzene ring and (Qm + Qp) the sum of the ESP-determined charges on those three atoms.

For CA I, their best equation was:

− log Ki = 11.74(±3.65)QS − 1.713(±0.621)D1 − 0.1956(±0.0457) log P

(5.8)

− 1.0062(±0.1571)pKa − 172.8(±62.0)SpE − 59.07(±13.0)

(n = 35, R2 = 0.762, s = 0.218)

where QS is the charge on the sulfonamide S, Dl the local dipole index (a measure of separation of charge), log P the lipophilicity calculated by the program ClogP, pKa the dissociation constant of the sulfonamide protons and SpE the electrophilic superdelocalizability of the p-carbon of the sulfanilamide benzene ring.

Clare and Supuran (1999) reported in an AM1 study of a series of 1,3- and 1,4- benzenedisulfonamides (Table 5.6) of the forms RSO2NHC6H4SO2NH2 (m and p), RSO2NHCH2C6H4SO2NH2 and RSO2NHCH2CH2C6H4SO2NH2 (both p) with one primary sulfonamide the QSARs for the inhibition of CA I, CA II and CA IV. For CA I, they obtained:

− log IC50 = −5.79(±2.12)QS − 4.26(±1.01)QH + 0.0326(±0.011)μ x

(5.9)

− 0.299(±0.108)EH − 0.600(±0.145)EL + 2.12 ∞10−3 (−1.14 ∞10−3 yy

+ 0.0209(±0.0088) HS − 3.13(±0.96)QC + 10.30(±5.58)

(n = 72, R2 = 0.619, s = 0.22)

where QS is the charge on the primary sulfonamide S; QH the charge on the secondary sulfonamide H; EH and EL are the energies of the HOMO and LUMO, respectively;

Copyright © 2004 CRC Press, LLC

QSAR Studies of Sulfonamide Carbonic Anhydrase Inhibitors

157

TABLE 5.6

Benzenedisulfonamides Studied by Clare and Supurana

 

SO2NH2

 

SO2NH2

SO2NH2

SO2NH2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HNSO2R

 

 

 

 

 

 

 

 

 

 

HNSO2R

 

CH2NHSO2R

CH2CH2NHSO2R

A

B

C

 

D

 

 

 

 

 

 

 

IC50

Drug

Type

R

1

A

Me

2

A

PhCH2

3

A

Me2N

4

A

Ph

5

A

4-Me-C6H4

6

A

2,4,6-Me3-C6H2

7

A

4-F-C6H4

8

A

4-Cl-C6H4

9

A

4-Br-C6H4

10

A

4-MeO-C6H4

11

A

2-HOOC-C6H4

12

A

2-O2N-C6H4

13

A

3-O2N-C6H4

14

A

4-O2N-C6H4

15

A

4-AcNH-C6H4

16

A

3-H2N-C6H4

17

A

4-H2N-C6H4

18

A

C6F5

19

A

4-Cl-3-O2N-C6H3

20

B

Me

21

B

PhCH2

22

B

Me2N

23

B

Ph

24

B

4-Me-C6H4

25

B

2,4,6-Me3-C6H2

26

B

4-F-C6H4

27

B

4-Cl-C6H4

28

B

4-Br-C6H4

29

B

4-MeO-C6H4

30

B

2-HOOC-C6H4

31

B

2-O2N-C6H4

32

B

3-O2N-C6H4

33

B

4-O2N-C6H4

34

B

4-AcNH-C6H4

CA I

CA II

CA III

125

64

98

109

17

51

114

12

30

103

49

85

96

42

83

69

55

60

40

9

15

38

9

13

35

8

10

44

30

14

26

7

10

29

11

18

33

10

21

31

10

22

245

82

164

168

43

114

164

46

129

11

3

7

60

12

31

176

79

125

150

28

77

210

31

65

295

77

126

301

76

110

98

67

81

65

10

22

44

9

14

40

9

12

59

40

48

32

7

20

33

10

26

35

9

22

36

10

24

298

101

188

Copyright © 2004 CRC Press, LLC

158

Carbonic Anhydrase

TABLE 5.6 (continued)

Benzenedisulfonamides Studied by Clare and Supurana

SO2NH2 SO2NH2 SO2NH2 SO2NH2

 

 

 

HNSO2R

 

 

 

 

 

 

 

 

 

 

HNSO2R

 

CH2NHSO2R

CH2CH2NHSO2R

A

B

C

 

D

 

 

 

 

 

 

 

IC50

Drug

Type

R

35

B

3-H2N-C6H4

36

B

4-H2N-C6H4

37

B

C6F5

38

B

4-Cl-3-O2N-C6H3

39

C

Me

40

C

PhCH2

41

C

Me2N

42

C

Ph

43

C

4-Me-C6H4

44

C

2,4,6-Me3-C6H2

45

C

4-F-C6H4

46

C

4-Cl-C6H4

47

C

4-Br-C6H4

48

C

4-MeO-C6H4

49

C

2-HOOC-C6H4

50

C

2-O2N-C6H4

51

C

3-O2N-C6H4

52

C

4-O2N-C6H4

53

C

4-AcNH-C6H4

54

C

3-H2N-C6H4

55

C

4-H2N-C6H4

56

C

C6F5

57

C

4-Cl-3-O2N-C6H3

58

D

Me

59

D

PhCH2

60

D

Me2N

61

D

Ph

62

D

4-Me-C6H4

63

D

2,4,6-Me3-C6H2

64

D

4-F-C6H4

65

D

4-Cl-C6H4

66

D

4-Br-C6H4

67

D

4-MeO-C6H4

CA I

CA II

CA III

176

47

129

185

50

144

14

3

10

74

15

46

104

51

87

96

10

45

90

8

21

81

40

64

85

31

60

60

52

57

33

7

12

29

7

10

24

5

8

43

18

29

21

6

10

24

10

16

25

9

17

20

6

11

205

77

149

123

35

86

109

33

72

10

2

4

58

11

27

93

40

71

81

8

38

75

6

13

69

28

39

70

27

54

46

40

45

28

5

9

24

5

8

19

3

7

38

15

25

Copyright © 2004 CRC Press, LLC

QSAR Studies of Sulfonamide Carbonic Anhydrase Inhibitors

159

TABLE 5.6 (continued)

Benzenedisulfonamides Studied by Clare and Supurana

SO2NH2 SO2NH2 SO2NH2 SO2NH2

 

 

 

HNSO2R

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HNSO2R

 

 

CH2NHSO2R

CH2CH2NHSO2R

A

B

 

C

 

D

 

 

 

 

 

 

 

 

 

IC50

 

Drug

Type

R

 

 

CA I

CA II

CA III

68

D

2-HOOC-C6H4

69

D

2-O2N-C6H4

70

D

3-O2N-C6H4

71

D

4-O2N-C6H4

72

D

4-AcNH-C6H4

73

D

3-H2N-C6H4

74

D

4-H2N-C6H4

75

D

C6F5

76

D

4-Cl-3-O2N-C6H3

15

5

9

22

6

9

22

8

13

20

4

10

187

75

119

101

30

84

95

30

72

8

1

3

50

9

21

a Clare, B.W., and Supuran, C.T. (1999) European Journal of Medicinal Chemistry 34, 463–474. With permission from Elsevier.

Πyy is the intermediate diagonal component of the polarization tensor; HS the calculated solvation energy; and QC the charge on the carbon atom bound to the primary sulfonamide S.

For CA II they obtained:

log IC50 = −2.63 103(±1.34 103 )Πyy 3.67 103(±1.23103 )Πzz (5.10)

0.0239(±0.0117)μ − 0.644(±0.173)EL + 0.115(±0.046)log P

+4.16(±1.14)QO + 0.592(±0.095)I3 + 7.50(±2.26)

(n = 72, R2 = 0.682, s = 0.24)

where Πzz is the diagonal component of the polarizability tensor along the axis of highest inertia, μ the magnitude of the dipole moment, log P the lipophilicity calculated by ClogP, QO the sum of the charges on the secondary sulfonamide oxygens and I3 is 1 if there are two carbon atoms between the secondary SO2NH group and the primary benzenesulfonamide ring (rather than 1 or 0) and 0 otherwise.

Copyright © 2004 CRC Press, LLC

160

Carbonic Anhydrase

For CA IV they obtained:

 

− log IC50

= 0.891(±0.317)QN − 0.322(±0.134)EH − 0.377(±0.166)EL

(5.11)

+0.921(±0.367)D1 + 0.184(±0.060) log P + 2.885(1.108)QO

+0.35(±0.101)I3 − 0.45(±2.16)

(n = 72, R2 = 0.661, s = 0.25)

where QN is the charge on the secondary sulfonamide N and the other symbols are as defined for Equation 5.9 and Equation 5.10. Equation 5.9 to Equation 5.11 benefit from having a large number of compounds studied.

5.2.2 STERIC EFFECTS, AREA, VOLUME AND POLARIZABILITY

The area and volume of molecules tend to correlate so closely that usually only one can enter a QSAR equation without introducing unacceptable collinearity. Polarizability, either as the tensor components or as their average, also correlates with size but not so strongly so as to preclude the use of both. Equation 5.5 presents a correlation with the Sterimol parameters obtained by Carotti et al. (1989), and Equations 5.9 and 5.10 correlations with components of the polarizability obtained by Clare and Supuran (1999).

5.2.3 LIPOPHILICITY

As with most other groups of drugs, lipophilicity enters the QSAR for CA inhibitors if a sufficiently large variety of drugs is examined. Thus, the results of Kakeya et al. (1969a, 1969b, 1969c, 1970) and Hansch et al. (1985) cited in Equations 5.2 and 5.3 involve lipophilicity, with higher lipophilicity favoring activity, and similarly in the work of Carotti et al. (1989) in Equations 5.4 and 5.5. Lipophilicity also plays a part in the more elaborate equations derived by Clare and Supuran (Clare and Supuran 1999; Supuran and Clare 1998) as shown in Equations 5.8, 5.10 and 5.11. Table 5.7 presents a study of the 4-, 5- and 6-substituted 1,3-benzenedisulfonamide inhibitors of chloroform CA (a mixture of CA I and CA II). Kishida and Manabee (1980) used only the substituent π values to explain activity. They gave the following equation:

–log IC50 = –0.2125π4 – 2.1814π5 + 2.8731(π6 – 0.6193)2 + 0.5674 (5.12)

(R = 0.9486, n = 19, F = 50.9414)

This obviously cannot be valid, as it treats the equivalent 4- and 6-positions differently. Altomare et al. (1991a) determined the lipophilicities of a number of benzene-

sulfonamide inhibitors of BCA B (Table 5.3) and gave the following equation:

Copyright © 2004 CRC Press, LLC

QSAR Studies of Sulfonamide Carbonic Anhydrase Inhibitors

161

TABLE 5.7

Activities and Structures of Disulfonamides Studied by Kishida and Manabea

SO2NH2

R3

 

R2

 

 

SO2NH2

 

 

 

 

 

R1

 

 

 

R1

R2

R3

108 IC50

a

H

H

H

100

b

Me

H

H

3.3

c

Et

H

H

25

d

i-Pr

H

H

25

e

F

H

H

10

f

Cl

H

H

11

g

Br

H

H

17

h

Me

Me

H

4

i

Me

H

Me

2.1

j

Me

H

F

3.6

k

Me

H

Cl

2.5

l

Me

Cl

H

0.5

m

Cl

Me

H

1.5

n

Me

H

Br

2.3

o

Et

H

Cl

1.8

p

n-Pr

H

Cl

1.8

q

Cl

Cl

H

0.5

r

Cl

H

Cl

1.5

s

Br

H

Br

2.5

t

Cl

H

F

2.5

u

Cl

H

Br

3.1

a Kishida, K., and Manabe, R.

(1980) Medical Journal of the Osaka

University 30, 95–100.

log 1/Ki = 0.91(±0.32)σ + 0.72(±0.15)π*ODP – 0.35(±0.11)B5,3 + 6.08(±0.23)

(n = 31, r = 0.918, s = 0.287)

(5.13)

where π*ODP is the new, chromatographically determined hydrophobic substituent constant. This equation is based on the same data as, and is comparable to, that in Equation 5.5.

Copyright © 2004 CRC Press, LLC

162

Carbonic Anhydrase

Altomare et al. (1991b) used chromatographic octanol–water and chloro-

form–water distribution coefficients to obtain the difference, log Poct–chf, which is a measure of hydrogen bond donor capacity of the substance. They derived for the

series of benzenesulfonamide inhibitors of BCA B, of a subset given in Table 5.3, the following equation:

log II50 = 0.65(±0.30)σ + 0.66(±0.34) log Poct–chf + 0.27(±0.31)

(5.14)

(n = 19, R = 0.89, s = 0.305)

5.2.4 QUANTUM MEASURES OTHER THAN CHARGE

Frontier orbital energies were recognized early as predictors of CA inhibitory activity. The energies of the HOMO and LUMO are always to be considered as potential candidates for descriptors in QSAR, especially with aromatic compounds, and have been found to correlate with CA inhibitory activity in benzenesulfonamide derivatives. Thus, DeBenedetti and Menziani (1985) studied the series of 25 substituted benzenesulfonamide inhibitors of human CA II (Table 5.4), using the CNDO/2 semiempirical method and found for the neutral form the following relationship:

log II50 = –2.038(±0.348)ELUMO + 1.629(±0.138)

(5.15)

(n = 23, r = 0.907, s = 0.278, F = 96.95)

and for the anion:

log II50 = –2.280(±0.335)EHOMO + 9.202(±1.511)

(5.16)

(n = 23, r = 0.928, s = 0.244, F = 131.0)

A novel correlate of CA inhibitory activity in benzene derivatives, only recently detected, is the direction of the nodes in certain near-frontier, π-like orbitals (Clare and Supuran 2001). These orbitals can be regarded as arising from the degenerate HOMO and LUMO of benzene, and the resultant splitting of energy is also implicated in the nonbonded interaction between the ligand and some aromatic residue in the enzyme. It is clear that if two π-like orbitals, one on the ligand and one on the enzyme, are to interact, a requirement is that nodes in the orbitals largely coincide. We have a procedure to approximately quantify this coincidence. For human CA II:

− log KI = −18.75(±17.44)QN − 3.252(±1.381)D1 + 0.2485(±0.1854) cos 2ΦH

− 0.0348(±0.2659)sin 2ΦH + 31.93(±20.22)

(5.17)

(N = 27, R2 = 0.706, Q2 = 0.555)

 

Copyright © 2004 CRC Press, LLC

QSAR Studies of Sulfonamide Carbonic Anhydrase Inhibitors

163

where QN is the charge on the sulfonamide N, Dl the local dipole index and ΦH the angle the node in the HOMO makes with the sulfonamide group at the center of the benzene ring. The numbers in parentheses are the 95% confidence limits.

A quantum measure that attempts a comprehensive description of molecules is quantum similarity. This generates between each pair of compounds numbers analogous to correlation coefficients. Thus, for property P(x,y,z) of drugs i and j, which are functions of the spatial coordinates x, y and z, a similarity measure can be defined, for example:

ρi,j = Pi Pjdr Pi2 dr Pj2 dr

where the integration is over all space and the two molecules are aligned to maximize ρ2. The property P can be any spatial property of the molecule, such as electron density, an orbital magnitude or electrostatic potential, and the similarity measure is analogous to a Pearson correlation coefficient. The electron density is a property of special interest. It is tedious to compute any of these quantities as it requires optimization of both conformation and alignment.

Amat and Carbo-Dorca (1999) have applied the concept of self-similarity, defined as ZAA = ρA (r) 2 dr, where ρA is the electron density, which avoids this problem, to CA inhibitors. Self-similarities can be substituted for classical descriptors such as Hansch π or Hammett σ. They treated the data of Hansch et al. (1985) and obtained the interesting equation, free from indicator variables, for inhibition of human CA C (now designated CA II):

log K = 1.2000θ

AA

− 2.3157θ SO2

+ 2.5149θ NH2

− 0.6264θmC

+ 7.4441 (5.18)

 

AA

AA

AA

 

(n = 29, R2 = 0.984, Q2 = 0.976)

Note that Equation 24 in Amat and Carbo-Dorca (1999) appears to have been misprinted. Here, the scaled self-similarity θAA splits into contributions from fragments. The correlation indicates the splitting of SO2NH2 into two subfragments SO2 and NH2, suggesting that the SO2NH2 binds at two points: the SO2 oxygen and the NH2 hydrogen. Such calculations can throw light on the details of the mechanism of drug activity.

5.2.5 TOPOLOGICAL INDICES

Although topological and graph theoretical indices are very difficult to interpret physically they can be good predictors of activity, and compared to quantum theoretical indices they are very quick and easy to calculate. These two kinds of descriptors should not be regarded as mutually exclusive, but the topological indices can be applied on large data sets, perhaps derived from combinatorial synthesis and high throughput screening, to select data sets for more laborious methods, which give fits of comparable quality but those that are much more interpretable.

Copyright © 2004 CRC Press, LLC